Navigation Links
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Date:4/15/2009

--New 12-month study broadens Phase 3 clinical program to further evaluate the benefits of Dimebon in Alzheimer's Disease--

NEW YORK and SAN FRANCISCO, April 15 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) today announced the initiation of a 12-month, Phase 3 clinical trial of the investigational drug Dimebon. The study, known as CONCERT, is designed to evaluate the safety and efficacy of Dimebon when added to ongoing treatment with donepezil HCI tablets, the leading Alzheimer's disease (AD) medication worldwide, in patients with mild-to-moderate AD.

The CONCERT study is part of a broad, Phase 3 clinical development program for Dimebon. The study builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase 3 program also includes the confirmatory 6-month CONNECTION study, which is designed to evaluate the safety and efficacy of Dimebon monotherapy in patients with mild-to-moderate AD and builds on results of the first pivotal trial of Dimebon in AD.

"Due to the complexity of Alzheimer's disease, the condition often requires combination treatment to help relieve symptoms and slow disease progression," said Bengt Winblad, professor of geriatrics, Karolinska Institute. "The CONCERT trial will explore the potential additive effects of Dimebon to ongoing donepezil therapy, two drugs thought to have different mechanisms of action. We believe this trial may serve to demonstrate the potential of Dimebon in AD."

Dimebon is an investigational compound cur
'/>"/>

SOURCE Pfizer Inc; Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
2. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. MannKind Addresses Pfizers Announcement Regarding Exubera
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... SHANGHAI, Oct. 24, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation ... "Company"), a leading China-based pharmaceutical and biotechnology research ... has, through its main Chinese subsidiary, Shanghai ChemPartner ... River Laboratories International, Inc.,s ("Charles River") Shanghai research ...
... and HOPKINTON, Mass., Oct. 24, 2011 DxTerity ... (NASDAQ: CALP ) announced today that ... strategic collaboration that will allow researchers to perform DxTerity,s ... platform minimizing sample processing time without compromising data quality. ...
Cached Medicine Technology:ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 2DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 3DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 4
(Date:12/24/2014)... The 2014 Market Research Report ... in-depth research report on COC industry. For an ... including its definition, classification, application, industry chain structure, ... report also presents product specification, manufacturing process, and ... regions, technology and applications. Analysis also covers upstream ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 For nearly ... blessings, housewarmings, new babies, graces, and all of life's ... poet and author, Nancy Tupper Ling, in Toasts: ... by Viva Editions. , Organized by category and ... that won't appear anywhere else, this timely tome contains ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 “ Relax ... its monthly AppWatch, which features the latest and coolest ... Andrew Tropeano, a mobile technology expert and host of ... how this application soothes users so they can fall ... 30% of adults say they have some sort of ...
(Date:12/24/2014)... Las Vegas, NV (PRWEB) December 24, 2014 ... Home Services reminds homeowners that before investing time ... start by consulting a licensed professional that specializes in ... who may plan to replace their water heater in ... making a final decision. , Greenstar Home Services ...
Breaking Medicine News(10 mins):Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2
... , EXTON, Pa., July 29 Kensey Nash Corporation (Nasdaq: ... results for its fourth quarter and fiscal year ended June 30, 2009 ... , , Joe Kaufmann, President and CEO, will be ... at 9:00 A.M. Eastern Time. , , ...
... American Association ... ... in Cancer Prevention Research , a journal of the American Association for Cancer Research, ... head and neck. Furthermore, African Americans had far less HPV infection than whites, which led ...
... , , , ARMONK, ... ) announced today that St. Elizabeth Healthcare is ... roll-out of electronic medical records to improve patient care and lower costs. ... ) , , Today, only 1.5 percent of U.S. hospital ...
... , COLUMBUS, Ohio, July 29 ... New Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by ... in 30mL bottles for immediate shipment to wholesalers and pharmacies ... Solution, 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. ...
... ... and share , ... Skokie, Ill. (Vocus) July 29, 2009 -- Tabyat Partners, LLC. ( www.tabyat.com ), a ... its Web-based communication portal iluvmydoc.com™ ( www.iluvmydoc.com ). The site offers interactive services to ...
... , BOSTON, July 29 Although acne ... extremely common in adult women. Studies show that acne affects more ... more than 25 percent of women between the ages of 40-49 ... to report having acne than men. While there is no cure ...
Cached Medicine News:Health News:Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference 2Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 2Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 3Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 4Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 2Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 3Health News:Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL 2Health News:Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 3Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: